History

Ipamorelin was developed in the late 1990s by Novo Nordisk (code NNC 26-0161), derived from the earlier peptide GHRP-1. Researchers led by Kirsten Raun described it in a 1998 paper as "the first selective growth hormone secretagogue," notable for triggering GH release without raising cortisol, ACTH, or prolactin. It acts on the ghrelin/growth-hormone-secretagogue receptor. Helsinn Therapeutics later tested it in Phase II trials for postoperative ileus, but development was discontinued for lack of efficacy. It has never gained regulatory approval.

Ipamorelin is a synthetic peptide that briefly raises growth hormone (GH) levels. It has been tested in humans, but the one trial that measured a real clinical outcome did not work, and it has never been approved for any use.

What it is

Ipamorelin is a pentapeptide (sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2) originally developed by Novo Nordisk under the code NNC 26-0161. It is a selective agonist of the ghrelin / growth-hormone-secretagogue receptor (GHS-R1a). Activating that receptor triggers a pulse of GH from the pituitary. Its main selling point in the research literature is selectivity: in studies it raised GH without meaningfully increasing ACTH, cortisol, or prolactin, which sets it apart from some older GH-releasing peptides.

The claims

Marketers and wellness clinics promote ipamorelin (often combined with CJC-1295) for muscle gain, fat loss, faster recovery, better sleep, anti-aging, and “natural” GH support. The implied logic is that a gentle, pulsatile GH boost delivers the benefits of growth hormone without the downsides of injecting GH directly.

What the evidence actually shows

Human data exist, but they are thin and not encouraging for these claims. A Phase 1 study in 40 healthy men (Gobburu et al., 1999) showed ipamorelin behaves like a small peptide: dose-proportional kinetics, a roughly 2-hour half-life, and a sharp GH spike peaking under an hour after dosing, then fading within about six hours. That confirms it does what it is designed to do biochemically.

The decisive test is what happens to actual outcomes. The most rigorous human trial was a randomized, double-blind, placebo-controlled Phase 2 study (NCT00672074) of intravenous ipamorelin for postoperative ileus in roughly 114 bowel-resection patients. It did not beat placebo: ipamorelin failed to significantly improve recovery of bowel function or shorten time to first tolerated meal (about 25 hours versus 33 hours on placebo, a difference that was not statistically significant), and development was discontinued for lack of efficacy. There are no published long-term human trials supporting the muscle, fat-loss, recovery, sleep, or anti-aging claims; that evidence is essentially absent. So the honest summary is: short-term human pharmacology is established, but the one meaningful clinical-outcome trial was negative, and the popular benefits are unproven.

Legal and regulatory status

Ipamorelin is not FDA-approved for any indication and never has been. Its compounding status has been restrictive. In September 2023 the FDA placed ipamorelin acetate in Category 2 of the interim 503A bulk-substances list, the category for substances the agency believes may present significant safety risks. It was removed from that list in September 2024 after the nomination was withdrawn, and the FDA’s Pharmacy Compounding Advisory Committee subsequently voted against adding ipamorelin to the 503A bulks list at its late-2024 meetings. The practical result, as of mid-2026, is that there is no established legal pathway for compounding pharmacies to use it, and it is sold mainly as a “research chemical,” which is not a quality or safety designation. In sport, the World Anti-Doping Agency prohibits ipamorelin at all times as a growth-hormone secretagogue (category S2); because it has no approved medical use, there is in practice no legitimate basis for a therapeutic use exemption.

Safety

There is no meaningful long-term human safety data. The available trials were short, so little is known about repeated or chronic use. General concerns for this drug class include sustained GH/IGF-1 elevation, effects on blood sugar and insulin sensitivity, and water retention. Product purity is a real-world risk because material sold outside approved channels is unregulated and may contain impurities. Nothing here is medical advice.

Bottom line

Ipamorelin reliably produces a short GH pulse in humans, but its single rigorous efficacy trial failed, the popular benefits are unproven, it is unapproved with no legal compounding route, and it is banned in sport.

Evidence grade: Preliminary human.